Novartis Investigative Site

Fortaleza, Ceará 60864-190

3 studies enrolling now · 25 studies all time

What they study most

Acromegaly, Acute Heart Failure, Acute Myocardial Infarction, Advanced Neuroendocrine Tumors of Pancreatic Origin, Atherosclerosis, Atypical Hemolytic Uremic Syndrome, Breast Cancer, Cardiovascular Disease, Chronic Heart Failure, Cushing's Disease, Ectopic ACTH Syndrome, Familial Hypercholesterolemia - Heterozygous

Studies at this site

• Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN — Recruiting now
• An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) — Recruiting now
• Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia — Recruiting now
• Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies — Recruiting now
• Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy — Completed
• Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) — Running, not enrolling
• Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent — Stopped early
• Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis — Stopped early
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
• Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease — Completed
• A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients — Completed
• Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF) — NO_LONGER_AVAILABLE
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Global Non-interventional Heart Failure Disease Registry — Stopped early
• An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. — Completed
• Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease — Completed
• Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly — Completed
• Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly — Completed
• A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation — Completed
• Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure — Completed
• Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin — Stopped early
• Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors — Completed
• Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early
• Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease — Completed